Organon Reports Positive Phase 3 VTAMA Data in Atopic Dermatitis
JERSEY CITY, N.J., July 24, 2026 Organon (NYSE: OGN) presented new post hoc pooled Phase 3 data from the...
Dermatology
Advertisement
Devonian Begins Pediatric Phase II/III Thykamine Trial
QUÉBEC, Canada, July 21, 2026 Devonian Health Group has received Health Canada authorization to initiate a Phase II/III clinical...
Galderma Launches Alastin in Japan and Asia Pacific to Expand Regenerative Skincare Portfolio
Zug, Switzerland | July 20, 2026 Galderma announced the expansion of its Alastin® regenerative skincare brand across the Japan...
Veradermics Presents VDPHL01 Data at AAD 2026
New Haven, Conn., July 17, 2026 Veradermics announced the presentation of new subgroup analysis data from its Phase 2/3...
InnoCare Reports Positive Phase II Soficitinib Results
Beijing, July 16, 2026 InnoCare Pharma announced that the Phase II portion of its adaptive Phase II/III clinical trial...
Advertisements
Castle Biosciences Wins NY Approval for AdvanceAD-Tx Test
FRIENDSWOOD, Texas, July 14, 2026 Castle Biosciences, Inc. has announced that its AdvanceAD-Tx™ test has received assay approval from...
Roche Enspryng Gains FDA Priority Review for TED Treatment
BASEL, Switzerland, June 30, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
AbbVie RINVOQ® Moves Closer to EU Approval for Alopecia Areata
NORTH CHICAGO, Ill., June 29, 2026 AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for...
Arcutis Secures FDA Approval for ZORYVE in Children Aged 2+
WESTLAKE VILLAGE, Calif., June 29, 2026 Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
AbbVie Secures FDA Approval for SKYRIZI in Pediatric Psoriatic Disease
NORTH CHICAGO, Ill., June 26, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI®...
Advertisement
